ailanthone has been researched along with Urinary Bladder Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrera, G; Cucci, MA; Damia, G; Dianzani, C; Grattarola, M; Pizzimenti, S; Ricci, F; Roetto, A; Trotta, F | 1 |
| Barrera, G; Cavalli, R; Cucci, MA; Daga, M; Dianzani, C; Ferrara, B; Grattarola, M; Pizzimenti, S; Scariot, V; Trotta, F | 1 |
2 other study(ies) available for ailanthone and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Ovarian Neoplasms; Oxidative Stress; Quassins; Urinary Bladder Neoplasms | 2020 |
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Humans; NF-E2-Related Factor 2; Phosphoproteins; Proto-Oncogene Proteins c-myc; Quassins; Transcription Factors; Urinary Bladder Neoplasms; YAP-Signaling Proteins | 2019 |